Pemvidutide
InvestigationalAlso known as: ALT-801, Altimmune dual agonist
Metabolic & Weight ManagementLast reviewed: April 28, 2026
A GLP-1/glucagon dual receptor agonist developed by Altimmune, similar in mechanism to survodutide. In Phase 2 trials (MOMENTUM), pemvidutide demonstrated up to 15.6% weight loss at 48 weeks with notable preservation of lean body mass — a differentiating feature compared to other weight loss drugs where significant muscle loss is a concern.
Mechanism of Action
Activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and food intake. Glucagon activation increases energy expenditure, promotes fat oxidation, and may help preserve lean mass during weight loss by shifting energy substrate utilization toward fat rather than protein catabolism.
Common Uses
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Lean mass preservation during weight loss
Known Risks
- GI side effects (nausea, diarrhea)
- Still in clinical trials — full safety profile not established
- Potential blood sugar effects
- Injection site reactions
Regulatory Status
Phase 2 completed (MOMENTUM trial). Phase 2b for MASH (IMPACT trial) ongoing. Altimmune reported 15.6% weight loss at 48 weeks with lean mass preservation. Phase 3 planning underway. The lean mass preservation claim is a key differentiator if confirmed in larger trials.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (investigational)
Typical Dose
1.8 mg or 2.4 mg (in clinical trials)
Frequency
Once weekly
Cycle Length
Ongoing — not commercially available
Not available outside clinical trials. The lean mass preservation data is particularly interesting for the fitness and longevity communities. Check clinicaltrials.gov for active trials.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.